Tinzaparin

Generic Name
Tinzaparin
Brand Names
Innohep
Drug Type
Small Molecule
Chemical Formula
-
CAS Number
9041-08-1
Unique Ingredient Identifier
7UQ7X4Y489
Background

Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III...

Indication

Tinzaparin is used for the prevention of postoperative venous thromboembolism in patients undergoing orthopedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism. It is also used for the treatment of deep vein thrombosis and/or pulmonary embolism. It is indicated for use in preventing c...

Associated Conditions
Clotting, Deep Vein Thrombosis, Pulmonary embolism, Deep vein thrombosis, Venous Thromboembolism
Associated Therapies
-

Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses

First Posted Date
2016-03-25
Last Posted Date
2018-12-13
Lead Sponsor
Maisonneuve-Rosemont Hospital
Target Recruit Count
28
Registration Number
NCT02719418
Locations
🇨🇦

Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada

Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer

First Posted Date
2014-10-09
Last Posted Date
2017-05-11
Lead Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Target Recruit Count
19
Registration Number
NCT02260414
Locations
🇫🇷

CHU de Saint-Etienne, Saint-Etienne, France

Use of Tinzaparin for Anticoagulation in Hemodialysis

First Posted Date
2013-08-28
Last Posted Date
2016-10-14
Lead Sponsor
Christine Ribic
Target Recruit Count
191
Registration Number
NCT01930396
Locations
🇨🇦

St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada

Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer

Phase 3
Completed
Conditions
Interventions
First Posted Date
2011-10-20
Last Posted Date
2021-05-17
Lead Sponsor
Ottawa Hospital Research Institute
Target Recruit Count
616
Registration Number
NCT01455831
Locations
🇧🇪

Ghent University Hospital, Ghent, Belgium

🇨🇦

Jewish General Hospital, Montreal, Quebec, Canada

🇨🇦

Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada

and more 13 locations

Can Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight?

First Posted Date
2011-07-08
Last Posted Date
2016-08-18
Lead Sponsor
University of Aarhus
Target Recruit Count
50
Registration Number
NCT01390051
Locations
🇩🇰

Consultant phD professor Anne-Mette Hvas, Aarhus, Central Denmark Region, Denmark

🇩🇰

Department of Obstetrics, Randers, Denmark

Venous Thromboembolism Prophylaxis Post Cesarean Section

First Posted Date
2011-03-24
Last Posted Date
2012-02-06
Lead Sponsor
King Saud University
Target Recruit Count
300
Registration Number
NCT01321788
Locations
🇸🇦

Security Forces Hospital, Riyadh, Saudi Arabia

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2009-09-22
Last Posted Date
2017-07-06
Lead Sponsor
University of Southern California
Target Recruit Count
131
Registration Number
NCT00981903
Locations
🇺🇸

Cornell Weill Scholl of Medicine, New York, New York, United States

🇺🇸

University of Southern California, Los Angeles, California, United States

Thromboprophylaxis for Patients Undergoing Surgical Resection for Colon Cancer

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2009-08-27
Last Posted Date
2014-10-22
Lead Sponsor
Ottawa Hospital Research Institute
Target Recruit Count
18
Registration Number
NCT00967148
Locations
🇨🇦

Ottawa Health Research Institute, Ottawa, Ontario, Canada

Safety and Efficacy of Therapeutic Anticoagulation With Tinzaparin During Pregnancy Via Weight-based Dosing

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-02-26
Last Posted Date
2013-08-15
Lead Sponsor
University of Calgary
Target Recruit Count
13
Registration Number
NCT00851864
Locations
🇨🇦

Calgary Health Region, Calgary, Alberta, Canada

Tinzaparin in the Treatment of the Acute Pulmonary Embolism

First Posted Date
2008-07-08
Last Posted Date
2009-02-13
Lead Sponsor
Complejo Hospitalario Xeral-Calde
Target Recruit Count
102
Registration Number
NCT00711308
Locations
🇪🇸

Pneumology Service. Hospital do Meixoeiro, Vigo, Pontevedra, Spain

🇪🇸

Pneumology Service. Hospital Clínico, Santiago de Compostela, A Coruña, Spain

🇪🇸

Pneumology Service. Hospital Xeral Cies, Vigo, Pontevedra, Spain

and more 1 locations
© Copyright 2024. All Rights Reserved by MedPath